SequelSEC

LABCORP HOLDINGS INC. LH

Services-Medical Laboratories · CIK 0000920148 · Fiscal year ends 1231

Revenue
$13.95B
Fiscal year ended 2025-12-31
Operating income
$1.38B
Fiscal year ended 2025-12-31
Free cash flow
$1.21B
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$21.70BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$263.35Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income24.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue1.6×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity2.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

Valuation over time

24.8× earnings today, against a median of 17.8× across 9 years on record. Above its own history.

Float measuredPublic floatFloat / net income
2025-06-30$21.70B24.8×
2024-06-28$16.40B22.0×
2023-06-30$17.30B41.4×
2022-06-30$20.20B15.8×
2021-06-30$24.80B10.4×
2020-06-30$15.20B9.8×
2018-06-30$16.10B18.2×
2017-06-30$14.90B12.1×
2016-06-30$12.70B17.8×

Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.

How this compares in its industry

Percentile among the Services-Medical Laboratories filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
SBC / revenue0.9%5th
FCF margin8.6%88th
Net margin6.3%86th
Operating margin9.9%86th
Long-term debt / equity0.59x29th
Revenue YoY growth7.2%30th
Current ratio1.42x32th
Gross margin28.8%42th
CapEx / revenue3.1%47th

LABCORP HOLDINGS INC. (LH) reported revenue of $13.95B and net income of $876.50M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from LABCORP HOLDINGS INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Medical Laboratories.

Income

LABCORP HOLDINGS INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$13.95B$13.01B$12.16B$11.86B$13.14B$13.98B$11.55B$11.33B$10.31B$9.55B
Cost of revenue$9.94B$9.38B$8.80B$8.16B$8.14B$9.03B$8.30B$8.16B$7.22B$6.70B
Gross profit$4.01B$3.62B$3.36B$3.71B$4.99B$4.95B$3.25B$3.18B$3.09B$2.85B
Operating income$1.38B$1.09B$725.60M$1.44B$3.05B$2.45B$1.33B$1.33B$1.31B$1.27B
Net income$876.50M$746.00M$418.00M$1.28B$2.38B$1.56B$823.80M$883.70M$1.23B$711.80M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 83.80Mshares 84.40Mshares 87.60Mshares 91.60Mshares 97.50Mshares 98.00Mshares 98.60Mshares 102.60Mshares 103.90Mshares 104.30M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$229.80M$212.40M$188.50M$233.90M$690.00M$662.10M$280.00M$384.40M-$155.40M$360.70M
Diluted EPS$10.46$8.84$4.77$13.97$24.39$15.88$8.35$8.61$11.81$6.82
Selling, general & administrative$2.22B$2.23B$2.02B$1.76B$1.69B$1.73B$1.62B$1.57B$1.50B$1.35B
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

LABCORP HOLDINGS INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$532.30M$1.52B$536.80M$320.60M$1.47B$1.32B$337.50M$426.80M$316.60M$433.60M
Total assets$18.39B$18.38B$16.73B$20.16B$20.39B$20.07B$18.05B$16.19B$16.67B$14.25B
Current assets$4.02B$4.81B$3.77B$4.62B$5.33B$5.13B$2.98B$2.84B$2.73B$2.48B
Total liabilities$9.76B$10.31B$8.83B$10.04B$10.09B$10.61B$10.46B$9.19B$9.85B$8.73B
Current liabilities$2.82B$3.33B$3.23B$3.08B$2.78B$3.08B$2.66B$1.88B$2.19B$1.83B
Total equity incl. NCI$8.62B$8.05B$7.88B$10.10B$10.27B$9.44B$7.64B$7.05B$6.80B$5.52B
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$534.70M$493.20M$474.60M$470.60M$401.40M$423.20M$244.70M$237.30M$227.20M$205.20M
Accounts receivable$2.10B$1.94B$1.91B$1.79B$2.26B$2.48B$1.54B$1.47B$1.53B$1.33B
Goodwill$6.79B$6.37B$6.14B$6.12B$5.89B$7.75B$7.86B$7.36B$7.40B$6.42B
Long-term debt$5.08B$5.33B$4.05B$5.04B$5.42B$5.42B$5.79B$5.99B$6.34B$5.30B
Accounts payable$840.80M$875.80M$827.50M$852.20M$621.30M$638.90M$632.30M$634.60M$573.90M$508.40M

Cash flow

LABCORP HOLDINGS INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow$1.64B$1.59B$1.33B$1.96B$3.11B$2.14B$1.44B$1.31B$1.50B$1.20B
Capital expenditures$434.50M$489.90M$453.60M$429.30M$421.50M$381.70M$400.20M$379.80M$312.90M$278.90M
Investing cash flow-$1.19B-$1.37B-$1.17B-$1.65B-$884.60M-$643.20M-$1.28B$206.70M-$2.23B-$795.70M
Financing cash flow-$1.46B$779.90M-$59.30M-$1.32B-$2.07B-$517.40M-$252.70M-$1.39B$593.20M-$671.00M
Net change in cash-$986.40M$981.90M$106.80M-$1.04B$151.90M$983.30M-$89.30M$110.20M-$116.90M-$282.80M
Stock-based compensation$125.80M$116.70M$128.70M$116.80M$132.90M$111.70M$107.00M$91.60M$109.70M$109.60M
Common dividends paid$240.70M$243.10M$254.00M$195.20M$0$0UnavailableUnavailableUnavailableUnavailable
Common share repurchases$450.00M$250.10M$1.00B$1.10B$1.67B$100.00M$450.00M$700.00M$338.10M$43.90M
Depreciation & amortization$681.10M$643.50M$577.30M$537.20M$577.00M$624.70M$577.20M$552.10M$533.20M$499.20M

Derived

LABCORP HOLDINGS INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow$1.21B$1.10B$874.10M$1.53B$2.69B$1.75B$1.04B$925.60M$1.19B$918.20M
Gross margin28.8%27.9%27.7%31.3%38.0%35.4%28.1%28.0%30.0%29.9%
Operating margin9.9%8.4%6.0%12.1%23.2%17.5%11.5%11.7%12.7%13.3%
FCF margin8.6%8.4%7.2%12.9%20.5%12.5%9.0%8.2%11.5%9.6%
SBC / revenue0.9%0.9%1.1%1.0%1.0%0.8%0.9%0.8%1.1%1.1%
Current ratio1.42x1.44x1.17x1.50x1.92x1.66x1.12x1.51x1.25x1.36x
Revenue YoY growth7.2%7.0%2.5%-9.7%-6.0%21.0%2.0%9.9%7.9%Unavailable
Net margin6.3%5.7%3.4%10.8%18.1%11.1%7.1%7.8%11.9%7.5%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue3.1%3.8%3.7%3.6%3.2%2.7%3.5%3.4%3.0%2.9%
Long-term debt / equity0.59xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-30View SEC filing
10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-10-31View SEC filing
10-Q · Filed 2025-08-01View SEC filing

Companies in the same industry

Reconciliation checks needing review

5 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2021-12-31

Difference 20600000 exceeds tolerance 20385400.000. Presentation or filing-vintage differences need review.

balance equationreview2020-12-31

Difference 20700000 exceeds tolerance 20071700.000. Presentation or filing-vintage differences need review.

balance equationreview2019-12-31

Difference 56800000 exceeds tolerance 18046400.000. Presentation or filing-vintage differences need review.

balance equationreview2018-12-31

Difference 57800000 exceeds tolerance 16185300.000. Presentation or filing-vintage differences need review.

balance equationreview2017-12-31

Difference 20800000 exceeds tolerance 16673000.000. Presentation or filing-vintage differences need review.